Tracking of Glycans Structure and Metallomics Profiles in <i>BRAF</i> Mutated Melanoma Cells Treated with Vemurafenib
Nearly half of patients with advanced and metastatic melanomas harbor a <i>BRAF</i> mutation. Vemurafenib (VEM), a BRAF inhibitor, is used to treat such patients, however, responses to VEM are very short-lived due to intrinsic, adaptive and/or acquired resistance. In this context, we pre...
Main Authors: | Monika K. Nisiewicz, Agata Kowalczyk, Anna Sobiepanek, Agata Jagielska, Barbara Wagner, Julita Nowakowska, Marianna Gniadek, Ireneusz P. Grudzinski, Tomasz Kobiela, Anna M. Nowicka |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/1/439 |
Similar Items
-
In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01) -
Ebola viral selenoproteins: a metallomics analysis
by: Somsri Wiwanitkit, et al.
Published: (2015-01-01) -
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
by: Paweł Rogala, et al.
Published: (2022-04-01) -
<i>BRAF</i> Inhibitors in <i>BRAF-Mutated</i> Colorectal Cancer: A Systematic Review
by: Wajeeha Aiman, et al.
Published: (2023-12-01) -
Seamless Coupling of Chemical Glycan Release and Labeling for an Accelerated Protein <i>N</i>-Glycan Sample Preparation Workflow
by: Mumtaz Kasim, et al.
Published: (2023-05-01)